Dr Reddy’s inks deal to sell US drugs in India
Dr Reddy's Laboratories has entered into an agreement with US-based biotechnology firm Amgen to sell its three drugs meant for heart and cancer patients in India. Terming it as a “strategic collaboration”, Dr Reddy’s said that it will undertake a full range of regulatory and commercial services to seek approval and launch the three medicines— Kyprolis, Blincyto and Repatha in the Indian market. “We are excited about our strategic collaboration with an innovation powerhouse like Amgen and look forward to making their innovative medicines accessible to Indian patients. Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and therefore, a priority for us at Dr Redy's," said Alok Sonig, Executive Vice-President and Head of India Business & Global Business Development of Dr Reddy's. The collaboration leverages capabilities of both companies, combining three of Amgen's innovative therapies with Dr Reddy's deep understanding of patient and physician needs in India, the company said in a statement. Amgen Vice President and General Manager, Japan Asia Pacific Region, Penny Wan said, “Dr Redy's has significant experience serving oncology and cardiovascular patients in India and shares Amgen's interest in delivering new treatment options to seriously ill patients.”
August 06, 2015 | 3:35pm IST.
to success.